Anti-PLA2R and anti-THS7DA Tests
•Serological diagnosis of primary membranous nephropathy (specificity up to 99%, prevalence up to 80%)
•Monitoring of disease course and therapy responses, risk assessment, and prognosis
•Worldwide exclusive test systems:
-Anti-PLA2R ELISA and Anti-PLA2R ChLIA for quantitative determination of anti-PLA2R antibodies
-IFA for separate or parallel detection of anti-PLA2R and anti-THS7DA antibodies (substrate: transfected cells)